KLK6

KLK6 (Kallikrein-Related Peptidase 6)

Diagram of KLK6 degradation mechanism

KLK6, also known as kallikrein-related peptidase 6, is a serine protease enzyme encoded by the KLK6 gene in humans. It is part of the kallikrein family, which consists of 15 serine proteases with diverse physiological functions. KLK6 is predominantly expressed in the central nervous system, but it is also found in other tissues such as the skin, breast, and ovaries.

Structure and Function

KLK6 is synthesized as a preproenzyme and undergoes post-translational modifications to become an active enzyme. The active form of KLK6 is involved in the degradation of extracellular matrix components, which is crucial for tissue remodeling and repair. It has been implicated in the regulation of cell migration, inflammation, and apoptosis.

Clinical Significance

KLK6 has been studied for its role in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Elevated levels of KLK6 have been observed in the cerebrospinal fluid of patients with these conditions, suggesting its potential as a biomarker for neurodegenerative diseases.

In addition to its role in the nervous system, KLK6 is also being investigated for its involvement in cancer progression. It has been found to be overexpressed in certain types of breast cancer and ovarian cancer, where it may contribute to tumor growth and metastasis.

Mechanism of Action

KLK6 exerts its effects by cleaving specific peptide bonds in target proteins. This proteolytic activity is regulated by inhibitors and activators that modulate its function in different physiological contexts. The diagram on the right illustrates the degradation mechanism of KLK6, highlighting its interaction with various substrates and inhibitors.

Research and Therapeutic Potential

Ongoing research is focused on understanding the precise role of KLK6 in health and disease. Therapeutic strategies targeting KLK6 activity are being explored, particularly in the context of neuroprotection and cancer therapy. Inhibitors of KLK6 are being developed to modulate its activity in pathological conditions.

Related Pages

• Kallikrein
• Serine protease
• Neurodegenerative disease
• Cancer biomarker